{
    "clinical_study": {
        "@rank": "97566", 
        "acronym": "OCT-DES", 
        "arm_group": [
            {
                "arm_group_label": "Resolute Integrity Stent", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will be randomised in a 1:1 ratio to receive two different types of DES"
            }, 
            {
                "arm_group_label": "Promus Stent", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients will be randomised in a 1:1 ratio to receive two different types of DES"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is a comparative evaluation of re-endothelailisation of the Integrity\n      Resolute zotarolimus eluting stent (Medtronic) and of the Promus Element erolimus eluting\n      stent (Boston Scientific), in patients with diabetes.\n\n      We plan to compare endothelial coverage and neointimal proliferation using OCT and compare\n      this data to published results from conventional stents."
        }, 
        "brief_title": "Comparison of Two New Generation Drug Eluting Stents in Patients With Diabetes (OCT-DES)", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "Diabetes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Diabetes Mellitus"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Known to have diabetes\n\n          -  Scheduled for percutaneous coronary intervention (PCI) with a stenosis suitable for\n             DES implantation and OCT imaging\n\n          -  Reference vessel diameter over 2.5mm by operator assessment.\n\n          -  Able to understand and sign the written Informed Consent Form.\n\n          -  Able and willing to follow the Protocol requirements.\n\n        Exclusion Criteria:\n\n          -  Inability to consent\n\n          -  Cardiogenic shock\n\n          -  Planned use of a bare metal stent\n\n          -  LMS coronary artery disease\n\n          -  Congestive cardiac failure or low ejection fraction (LVEF <35%)\n\n          -  Lesions unsuitable for OCT\n\n          -  Total length of stented lesion greater than 55mm (total combination of stent lengths)\n\n          -  Age less than 18 years or age greater than 80 years\n\n          -  Planned surgical procedure \u2264 12 months post PCI procedure\n\n          -  Patient demonstrates evidence of thrombocytopenia (platelet count < 100,000/mm3)\n\n          -  Patients with contraindications to ASA, clopidogrel, or prasogrel\n\n          -  Patient is currently on warfarin, or possibility of treatment with warfarin during\n             the following 12 months post index procedure\n\n          -  Allergy to contrast\n\n          -  Patients enrolled in another active clinical trial.\n\n          -  Potential for non-compliance towards the requirements in the study protocol.\n\n          -  Serious known concomitant disease with a life expectancy of less than one year\n\n          -  Follow-up impossible (no fixed abode, etc)\n\n          -  Patients with renal impairment (Creatinine >200mmol/L)\n\n          -  Subjects of childbearing potential"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060357", 
            "org_study_id": "11/LO/0948"
        }, 
        "intervention": {
            "arm_group_label": [
                "Resolute Integrity Stent", 
                "Promus Stent"
            ], 
            "intervention_name": "Optical coherence tomography", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetes Mellitus", 
            "PCI", 
            "Drug eluting stent", 
            "OCT"
        ], 
        "lastchanged_date": "February 7, 2014", 
        "location": {
            "contact": {
                "email": "stephenmark.hamshere@bartshealth.nhs.uk", 
                "last_name": "Stephen M Hamshere, MBBS", 
                "phone": "+442085892213"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "E2 9JX"
                }, 
                "name": "London Chest Hospital, Barts Health NHS Trust"
            }, 
            "investigator": [
                {
                    "last_name": "Stephen M Hamshere, MBBS", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Anthony Mathur, FRCP FESC", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Two New Generation Drug Eluting Stents in Patients With Diabetes", 
        "overall_contact": {
            "email": "stephenmark.hamshere@bartshealth.nhs.uk", 
            "last_name": "Stephen Hamshere, MBBS", 
            "phone": "+442085892213"
        }, 
        "overall_official": {
            "affiliation": "Barts & The London NHS Trust", 
            "last_name": "Anthony Mathur, FRCP FESC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Research Ethics Committee: United Kingdom", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Endothelial coverage expressed as % of struts without coverage as measured by OCT", 
            "measure": "Endothelial stent coverage", 
            "safety_issue": "No", 
            "time_frame": "6 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060357"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Barts & The London NHS Trust", 
            "investigator_full_name": "Anthony Mathur", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Neointimal hyperplasia (mm2) as measured by OCT", 
                "measure": "Neointimal hyperplasia", 
                "safety_issue": "No", 
                "time_frame": "6 month"
            }, 
            {
                "description": "death, heart failure, myocardial infarction, stroke, need for repeat revascularisation", 
                "measure": "MACE", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Barts & The London NHS Trust", 
        "sponsors": {
            "collaborator": {
                "agency": "Medtronic", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Barts & The London NHS Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}